Cytodyn, Inc.
Clinical trials sponsored by Cytodyn, Inc., explained in plain language.
-
Weekly shot could replace daily HIV pills for some patients
Disease control CompletedThis study tested whether a weekly injection of PRO 140 (Leronlimab) could keep HIV under control in people whose virus was already suppressed by daily pills. Over 500 participants switched from their regular medication to the shot alone for 48 weeks. The goal was to see how many…
Phase: PHASE2, PHASE3 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental drug targets hard-to-treat cancers with unique marker
Disease control CompletedThis study tested an experimental drug called leronlimab in 16 adults with advanced solid tumors that have a specific protein (CCR5) on their cells. The main goals were to check safety and see if the drug could slow tumor growth. Participants had already tried other treatments wi…
Phase: PHASE2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental drug leronlimab tested in 484 severe COVID-19 patients
Disease control CompletedThis study tested a drug called leronlimab in 484 hospitalized adults with severe or critical COVID-19. Participants received weekly injections of the drug or a placebo to see if it could lower the risk of death and improve recovery. The trial is now complete, and results help un…
Phase: PHASE2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New HIV drug shows promise in small trial for Drug-Resistant patients
Disease control CompletedThis trial tested an injectable drug called PRO 140 (Leronlimab) in 6 people with HIV who had developed resistance to standard medications. The goal was to see if adding PRO 140 to their current failing therapy could reduce the amount of virus in their blood. The study lasted 25 …
Phase: PHASE2, PHASE3 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:57 UTC